# NYU Langone Health: Phase 2 study in Early-stage Breast Cancer, Fear of Cancer Recurrence (100 participants)

**Score:** 80/100

| Field | Value |
|---|---|
| Sponsor | NYU Langone Health |
| Sponsor type | Academic and hospital |
| Study | Psilocybin FCR Early-Stage Breast Cancer |
| NCT ID | NCT07909408 |
| Phase | Phase 2 |
| Status | not yet recruiting |
| Conditions | Early-stage Breast Cancer; Fear of Cancer Recurrence; Anxiety; Depression |
| Intervention types | drug |
| Target enrollment | 100 |
| Site countries | United States |
| Posted | 2026-11-02 |
| Planned start | 2027-01-02 |
| Event | Newly registered study |
| Event date | 2026-11-02 |

## Why this score
- Posted in the last two weeks.
- Phase 2: multi-site, larger budget.
- 100 participants planned.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07909408). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.